Nurix Therapeutics, Inc. · NASDAQ:NRIX
Nurix Therapeutics — EHA 2026 Annual Meeting
15 slides from Nurix Therapeutics's conference presentation, Jun 14, 2026
Slide 1: Updated efficacy and safety data from phase 1a/b trial of bexobrutideg in CLL/SLL
Updated efficacy and safety data from an ongoing phase 1a/b trial of the BTK degrader bexobrutideg (NX-5948) in patients with CLL/SLL across lines of therapy 1Talha Munir, 2Zulfa Omer, 3Sebastian Grosicki, 4Michal Kwiatek, 5Alexey Danilov, 6Nirav N. Shah, 7Francesco Forconi, 8Alvaro Alencar, 9,10Mar
Slide 2: Bexobrutideg (NX-5948)
Bexobrutideg (NX-5948) A novel CNS-penetrant BTK degrader that addresses BTK scaffolding and overcomes BTK resistance mutations Active against not only wildtype BTK but also treatment emergent BTK-inhibitor resistance mutations1,2 Addresses both BTK scaffolding and kinase functions, unlike curre
Slide 3: Superior Mutation Coverage and Highly Selective BTK Degradation
Bexobrutideg Shows Superior Mutation Coverage and Highly Selective BTK Degradation Bexobrutideg shows superior cell killing across Global proteomics using bexobrutideg show selective mutations compared with BTK inhibitors* degradation of BTK at clinically relevant exposures GI-50 (nM) 0 Most Bexobru
Slide 4: Bexobrutideg Trial Design (NX-5948-301, CLL/SLL Cohorts, Phase 1a/b)
Bexobrutideg Trial Design (NX-5948-301, CLL/SLL Cohorts, Phase 1a/b) Including Phase 1b cohorts with BTKi-treated and BCL2i-naïve; BTKi-naïve (including treatment-naïve) Phase 1a Phase 1b randomized Phase 1b dose expansion Relapsed/refractory CLL/SLL Relapsed/refractory CLL/SLL Earlier lines of trea
Slide 5: Bexobrutideg Safety Summary: All CLL/SLL Patients (Phase 1a/b)
Bexobrutideg Safety Summary: All CLL/SLL Patients (Phase 1a/b) TEAEs consistent between overall population and patients receiving 600 mg dose All patients with CLL/SLL 600 mg dose patients 50–450 mg dose patients n (%) (n=142) (n=86) (n=56) Any TEAE 134 (94.4) 79 (91.9) 55 (98.2) Treatment related 1
Slide 6: TEAEs in ≥10% of Patient Population (Phase 1a/b)
TEAEs in ≥10% of Patient Population (Phase 1a/b) Tolerable AE profile: comparable between overall population and patients receiving 600 mg dose TEAEs (all doses, n=142) TEAEs (600 mg dose, n=86) Purpura/contusiona Purpura/contusion Neutropeniab Neutropenia Petechiae Petechiae Diarrhea Diarrhea • Tol
Slide 7: Patient Disposition and Baseline Characteristics (Phase 1a)
Patient Disposition and Baseline Characteristics (Phase 1a) Patients with relapsed/refractory CLL/SLL Relapsed/refractory CLL/SLL Relapsed/refractory CLL/SLL Phase 1a: Dose escalation Characteristics 50–600 mg* (n=48) Phase 1a (n=48) Median age, years (range) 68.5 (35.0–88.0) Male, n (%) 32 (66.7) W
Slide 8: Bexobrutideg PFS and ORR in Relapsed/Refractory Patients (Phase 1a)
Bexobrutideg PFS and ORR in Relapsed/Refractory Patients (Phase 1a) PFS remains durable with a median of 22.1 months Relapsed/refractory CLL/SLL 1.0 PFS summary Progression-free survival probability Event-free rate n=48 0.8 18 months Median PFSa, months (95% CI) 22.1 (14.0–NR) 55.8% 0.6 ORR summary
Slide 9: Patient Disposition (Phase 1b Cohorts 5 and 15)
Patient Disposition (Phase 1b Cohorts 5 and 15) Patients with CLL/SLL in earlier lines of treatment Earlier lines of treatment CLL/SLL BTKi-treated and BTKi-naïve (including BCL2i-naïve treatment-naïve) Phase 1b Cohort 5 Phase 1b Cohort 15 (n=19)a (n=20) Discontinued Discontinued treatment (n=1) tre
Slide 10: Baseline Characteristics (Phase 1b Cohorts 5 and 15)
Baseline Characteristics (Phase 1b Cohorts 5 and 15) Patients in earlier lines of treatment Earlier lines of treatment CLL/SLL BTKi-treated and BCL2i-naïve BTKi-naïve (including treatment-naïve) Phase 1b Cohort 5 Phase 1b Cohort 15 Characteristics (n=19) (n=20) Median age, years (range) 71.0 (48.0–7
Slide 11: ORR in Earlier Lines of Treatment (Phase 1b Cohorts 5 and 15)
ORR in Earlier Lines of Treatment (Phase 1b Cohorts 5 and 15) Promising response rates in BCL2i-naïve, BTKi-naïve and treatment-naïve patients Earlier lines of treatment CLL/SLL BTKi-treated and BCL2i-naïve BTKi-naïve (including treatment-naïve) Phase 1b Cohort 5 Phase 1b Cohort 15 (n=14) (n=19) ORR
Slide 12: Time on Treatment in Patients Receiving Earlier Lines of Treatment
Time on Treatment in Patients Receiving Earlier Lines of Treatment Rapid and durable responses noted in most patients CIT BCL2i BTKi BTKi-treated and BCL2i-naïve ncBTKi Phase 1b Cohort 5 BTKi-naïve (including BTKi-naïve treatment- (including naïve) treatment- naïve) Phase 1b Cohort 15 Phase 1b Cohor
Slide 13: Reduction in Lymph Node Size in Patients Treated with Bexobrutideg
Reduction in Lymph Node Size in Patients Treated with Bexobrutideg Bexobrutideg demonstrates broad clinical activity including in high-risk patients Relapsed/refractory CLL/SLL Earlier lines of treatment CLL/SLL Phase 1a dose escalation, all doses BTKi-treated and BTKi-naïve % change from baseline i
Slide 14: Conclusions
Conclusions • Bexobrutideg is a highly selective, CNS penetrant degrader of both wild type BTK and BTKi resistance mutations that eliminates both the kinase and scaffolding functions of the BTK protein • In the Phase 1a portion of trial NX-5948-301, bexobrutideg demonstrated an ORR of 83% with a med
Slide 15: Acknowledgments
Acknowledgments • The authors are grateful to the patients who enrolled in the NX-5948-301 trial and their families • The authors would also like to thank: – All NX-5948-301 investigators and study site staff in France, Italy, the United States, the United Kingdom, the Netherlands, Poland, Spain, an